Abstracts tagged "race/ethnicity"

Abstract Number: 0594 • ACR Convergence 2021
The Burden of Systemic Lupus in Five Distinct Racial and Ethnic Groups in Israel: A Population-based Study
Titilola Falasinnu¹, Nada Rizk¹, Becca Feldman², Devy Zisman³, Michael Leshchinsky², Gabriella Lawrence², Yashaar Chaichian⁴ and Julia Simard¹, ¹Stanford School of Medicine, Stanford, CA, ²Clalit Research Institute, Clalit Health Services, Ramat Gan, Israel, ³Carmel Medical Center, Haifa, Israel, ⁴Stanford University, Los Gatos, CA
Background/Purpose: Misclassification of race and ethnicity in data can impact how disparities in prevalence, incidence, severity, and complications of systemic lupus erythematosus (SLE) are interpreted.…
Abstract Number: 1616 • ACR Convergence 2021
Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley
Sukesh Sukumaran¹, Reshma Patel² and Deepika Singh³, ¹Valley Children's Healthcare, Madera, CA, ²Valley Children's Hospital, Madera, CA, ³Valley Children Healthcare, Madera, CA
Background/Purpose: The U.S. FDA has expanded the emergency use authorization of the COVID-19 vaccine to include children >12 years of age. Gaining an understanding of…
Abstract Number: 0596 • ACR Convergence 2021
Racial Disparities in US Adults with Systemic Lupus Erythematosus: Prevalence, Quality of Life, Comorbidities and Healthcare Costs
Shannon Grabich¹, Cullen Seal², Robert Ortmann³ and Sandra Sze-jung Wu⁴, ¹Xcenda, Durham, NC, ²Xcenda, Carrollton, TX, ³AstraZeneca, Greenwood, IN, ⁴AstraZeneca, Wilmington, DE
Background/Purpose: SLE is a chronic, multisystem autoimmune disease characterized by reoccurring flares and remissions. It is more common among Asian, Black, and Hispanic populations. Racial…
Abstract Number: 1680 • ACR Convergence 2021
Impact of Race on the Efficacy and Safety of Tofacitinib in Patients with RA: A Post Hoc Analysis of Phase 2, 3, and 3b/4 Clinical Trials
Grace Wright¹, Eduardo Mysler², Yi-Hsing Chen³, Cassandra Kinch⁴, Arne Yndestad⁵, Kenneth Kwok⁶, Mary Jane Cadatal⁷, Rebecca Germino⁸ and Alexis Ogdie⁹, ¹Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, ²Organización Médica de Investigación, Buenos Aires, Argentina, ³Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁴Pfizer Canada ULC, Kirkland, QC, Canada, ⁵Pfizer Inc, Oslo, Norway, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Manila, Philippines, ⁸Pfizer Inc, Groton, CT, ⁹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: While racial disparities in clinical outcomes for RA patients (pts) receiving bDMARDs or csDMARDs have been described,1 there remains a paucity of data on…
Abstract Number: 0598 • ACR Convergence 2021
Differences in Discoid Lupus Erythematosus Skin Lesion Distribution and Characteristics in Black and Non-Black Patients: A Retrospective Cohort Study
Adrienne Joseph, Brandon Windsor, Linda Hynan and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Epidemiological studies have shown that discoid lupus erythematosus (DLE) has a higher incidence and prevalence in minorities, particularly Black individuals. Racial differences in clinical…
Abstract Number: 1726 • ACR Convergence 2021
A Pregnancy Planning Quality Score to Assess a Systematic Intervention to Improve Pregnancy Planning for Women with SLE
Catherine Sims¹, Amanda Eudy¹, Jayanth Doss¹, Lisa Criscione-Schreiber², Kai Sun², Rebecca Sadun¹, Jennifer Rogers² and Megan Clowse³, ¹Duke University, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Chapel Hill, NC
Background/Purpose: The safest pregnancies for women with SLE coincide with periods of disease quiescence maintained by pregnancy-compatible medications. In the US, Black women are more…
Abstract Number: 0601 • ACR Convergence 2021
Racial Differences in Medication Beliefs Among SLE Patients
D Ryan Anderson¹, Amanda Eudy², Megan Clowse³, Rebecca Sadun², Jennifer Rogers², Lisa Criscione-Schreiber⁴, Jayanth Doss², Corrine Volis⁵, Theresa Coles² and Kai Sun², ¹Duke University Hospital, Durham, NC, ²Duke University, Durham, NC, ³Duke University, Chapel Hill, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Medication adherence is essential to establishing and maintaining disease remission among SLE patients. Patients’ beliefs about treatment influence engagement and adherence to therapy. We…
Abstract Number: 1755 • ACR Convergence 2021
Increasing Participation of Underrepresented Groups in Lupus Clinical Trials: Insights from Qualitative Interviews with Patients and Physicians
Saira Sheikh¹, Maria Naylor², Becky Lane², Jennifer Sacks², Janine Gaiha-Rohrbach² and Cherie Butts², ¹University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ²Biogen, Cambridge, MA
Background/Purpose: Systemic lupus erythematosus disproportionately affects Black/African American (AA) and Latino/a populations.1 Challenges to engage and include these populations in clinical trials (CTs) can be…
Abstract Number: 0604 • ACR Convergence 2021
Disparities in Burden of Disease in Patients with RA Across Racial and Ethnic Groups
Jacqueline O’Brien¹, Sang Hee Park², Taylor Blachley¹, Maya Marchese¹, Nicole Middaugh¹, Xue Han², Keith Wittstock² and Leslie Harrold¹, ¹CorEvitas, LLC, Waltham, MA, ²Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Prior research has shown that differences exist in disease activity and clinical outcomes for RA across racial and ethnic groups in the US.1 This…
Abstract Number: 1780 • ACR Convergence 2021
Racial Disparities in Comorbidities of Patients with Psoriatic Arthritis
Sabahath Jaleel¹, Yael Ross¹ and Marina Magrey², ¹Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²Case Western Reserve Universtiy at MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Racial heterogeneity of the US population makes it imperative to study the racial differences in clinical characteristics, medication use and co-morbidities of PsA patients…
Abstract Number: 0060 • ACR Convergence 2020
ANCA-associated Vasculitis in Caucasian and Hispanics of the Inland Empire of Southern California
Sandy Lee¹, Patil Injean¹, Paulina Tran², Deepa Panikkath¹ and Christina Downey¹, ¹Loma Linda University Medical Center, Redlands, CA, ²UC Riverside School of Medicine, Riverside, CA
Background/Purpose: ANCA-associated vasculitis (AAV) is often studied in the Caucasian population with few studies looking at the disease in other races. Disease presentation and treatment…
Abstract Number: 1196 • ACR Convergence 2020
Associations of Biological Sex with Interstitial Lung Disease in Patients with Rheumatoid Arthritis Are Independent of Other Known Risk Factors
Austin Wheeler¹, Gail Kerr², Ilona Jileaeva³, Asha Krishna⁴, Bryant England¹, Harlan Sayles¹, Geoffrey Thiele¹, Jill Poole¹, Alison Petro¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Washington DC VA Medical Center, Washington, DC, ³Howard University Hospital, Washington, DC, ⁴Washington, D.C. VAMC, Washington, DC
Background/Purpose: Extra-articular manifestations of rheumatoid arthritis (RA), such as nodules and interstitial lung disease (ILD), portend poor outcomes and are more common in men than…
Abstract Number: 0242 • ACR Convergence 2020
Autoantibody Profile and Ethnicity: Risk Factors for Accelerated Development of Lupus Nephritis
Majed Albirdisi¹, David d'Cruz², Shirish Sangle² and Natasha Jordan³, ¹King Fahad Medical City, riyadh, Saudi Arabia, ²guys and st thomas hospital, london, United Kingdom, ³addebrooke's hospital, cambridge, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease. African ancestry is associated with an increased risk of Lupus Nephritis (LN). Anti-DNA autoantibodies play…
Abstract Number: 1258 • ACR Convergence 2020
Trajectory of Damage Accrual in African-American vs. Caucasian Systemic Lupus Erythematosus
Romy Kallas¹, Jessica Li², Daniel Goldman³ and Michelle Petri³, ¹Johns Hopkins Medical Institution, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: African-Americans have a higher incidence/prevalence of SLE, more lupus nephritis, higher rates of end stage renal disease and higher mortality than Caucasians. The aim…
Abstract Number: 0245 • ACR Convergence 2020
Systemic Lupus Erythematosus Phenotype Risk Score Identifies Undiagnosed Cases in a Large Electronic Health Record
April Barnado¹, Robert Carroll¹ and Lee Wheless¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease with patients often presenting with non-specific symptoms that can cause delays in diagnosis. Phenotype risk scores…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].